Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

2,357 recalls · Class II, newest first

Class II · Moderate risk

Lisinopril and Hydrochlorothiazide Tablets USP 20mg/12.5mg

Product Mix Up: This product is being recalled because of a complaint received that a sealed bottle of lisinopril and hydrochlorothiazide tablets 20mg/12.5 mg had a foreign tablet identified as atazanavir and ritonavir tablet 300mg/100mg.

Ongoing Labeling / mix-up Lupin Pharmaceuticals Inc. NDC 68180-519-01 D-0532-2025
Class II · Moderate risk

Gabapentin Capsules

Defective container; blister packaging inadequately sealed.

Ongoing Packaging defect The Harvard Drug Group LLC NDC 55154-3363-0 D-0508-2025
Class II · Moderate risk

Gabapentin Capsules

Defective container; blister packaging inadequately sealed.

Ongoing Packaging defect The Harvard Drug Group LLC NDC 0904-6665-61 D-0507-2025
Class II · Moderate risk

Lisdexamfetamine Dimesylate Capsules

Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 9 month long term stability station (25¿C, 60%RH).

Ongoing Dissolution failure Sun Pharmaceutical Industries INC NDC 57664-051-88 D-0516-2025
Class II · Moderate risk

LIDOcaine HCl Injection

Lack of Assurance of Sterility: A recent FDA inspection revealed concerns with the sterile manufacturing process.

Ongoing Sterility / contamination Tailstorm Health INC NDC 81483-0000-0 D-0498-2025
Class II · Moderate risk

Testo-200

Marketed Without an Approved NDA/ANDA

Ongoing Unapproved drug Advanced Pharmaceutical Technology, Inc. NDC 57377-200-01 D-0531-2025
Class II · Moderate risk

Gentamicin Injection

Failed Stability Specifications: Out of specification results for the Color Absorbance test during 12 Month sample analysis.

Ongoing Stability / shelf life Eugia US LLC NDC 55150-401-01 D-0472-2025

Recalls by year